Novo Nordisk’s Wegovy Gets EU Thumbs Up But Launch Will Wait
Based On Positive Phase III Data
Wegovy is set to join Saxenda as the company’s second EU approved drug for obesity, helping it corner the region’s weight-management market, once the company gets its supply back on track.
